Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment
Introduction: Intra-arterial hepatic (IAH) treatment has shown promising results in the management of patients with unresectable colorectal liver metastases (CRLM) the prognosis of which is poor. Bevacizumab adjunction to standard chemotherapy has been shown to improve survival of this patient popul...
Main Authors: | Eugénie Rigault, Benjamin Lacas, Olivier Glehen, Denis Smith, Eric Dupont-Bierre, Rosine Guimbaud, David Malka, Valérie Boige, Alina Fuerea, Jean-Pierre Pignon, Michel Ducreux |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-01-01
|
Series: | Cancer Treatment and Research Communications |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294222001654 |
Similar Items
-
Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease
by: Ruth Gabriela Herrera-Gómez, et al.
Published: (2022-06-01) -
Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
by: Tetsu Tomonari, et al.
Published: (2023-02-01) -
Intravitreal bevacizumab versus bevacizumab and 1 mg triamcinolone acetonide in eyes with bilateral diabetic macular edema
by: Sever Ozkan, et al.
Published: (2019-01-01) -
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
by: Masatoshi Kudo, et al.
Published: (2023-11-01) -
Bevacizumab for Glioblastoma—A Promising Drug or Not?
by: Ryo Nishikawa, et al.
Published: (2013-11-01)